ES2546933T3 - Vacunas de subunidades contra el PRRSV - Google Patents

Vacunas de subunidades contra el PRRSV Download PDF

Info

Publication number
ES2546933T3
ES2546933T3 ES05766550.7T ES05766550T ES2546933T3 ES 2546933 T3 ES2546933 T3 ES 2546933T3 ES 05766550 T ES05766550 T ES 05766550T ES 2546933 T3 ES2546933 T3 ES 2546933T3
Authority
ES
Spain
Prior art keywords
prrsv
exposure
group
clones
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05766550.7T
Other languages
English (en)
Spanish (es)
Inventor
Eric M. Vaughn
Richard Stammer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Application granted granted Critical
Publication of ES2546933T3 publication Critical patent/ES2546933T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES05766550.7T 2004-06-17 2005-06-17 Vacunas de subunidades contra el PRRSV Expired - Lifetime ES2546933T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US154617 1993-11-18
US58135004P 2004-06-17 2004-06-17
US581350P 2004-06-17
US11/154,617 US7722878B2 (en) 2004-06-17 2005-06-16 PRRSV subunit vaccines
PCT/US2005/021973 WO2006002193A2 (en) 2004-06-17 2005-06-17 Prrsv subunit vaccines

Publications (1)

Publication Number Publication Date
ES2546933T3 true ES2546933T3 (es) 2015-09-30

Family

ID=35431312

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05766550.7T Expired - Lifetime ES2546933T3 (es) 2004-06-17 2005-06-17 Vacunas de subunidades contra el PRRSV

Country Status (14)

Country Link
US (1) US7722878B2 (cg-RX-API-DMAC7.html)
EP (1) EP1755664B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008503221A (cg-RX-API-DMAC7.html)
KR (1) KR20070028431A (cg-RX-API-DMAC7.html)
AR (1) AR049825A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005258092A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510930A (cg-RX-API-DMAC7.html)
CA (1) CA2570778A1 (cg-RX-API-DMAC7.html)
DK (1) DK1755664T3 (cg-RX-API-DMAC7.html)
ES (1) ES2546933T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA06014821A (cg-RX-API-DMAC7.html)
RU (1) RU2007101531A (cg-RX-API-DMAC7.html)
TW (1) TW200603825A (cg-RX-API-DMAC7.html)
WO (1) WO2006002193A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
JP3961222B2 (ja) 1999-03-08 2007-08-22 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｐｒｒｓｖワクチン
ES2348159T3 (es) 1999-04-22 2010-11-30 United States Department Of Agriculture Vacuna contra el sindrome respiratorio y reproductivo porcino basada en el aislado ja-142.
MXPA06015105A (es) 2004-06-18 2007-03-26 Univ Minnesota Identificacion de organismos viralmente infectados y vacunados.
US7632636B2 (en) 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
DK1904631T3 (da) 2005-06-24 2012-08-13 Univ Minnesota PRRS-vira, infektiøse kloner, mutanter deraf samt anvendelsesfremgangsmåder
US8436337B2 (en) * 2009-05-12 2013-05-07 The State of Oregon Acting By and Through The State Board of Higher Education on Behalf of Oregon State Unitiversity Amorphous multi-component metallic thin films for electronic devices
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
BR112013020966B1 (pt) 2011-02-17 2020-05-26 Boehringer Ingelheim Vetmedica Gmbh Processo em escala comercial para produção do prrsv
CA2826341C (en) 2011-02-17 2022-02-22 Boehringer Ingelheim Vetmedica Gmbh Live attenuated strain of european prrsv and vaccines thereof
US20140302310A1 (en) * 2011-03-18 2014-10-09 The State of Oregon Acting by and Through the State Board of Higher Education on Behalf of Or... Amorphous multi-component metal/metal oxide nanolaminate metamaterials and devices based thereon
WO2012153160A1 (es) 2011-05-07 2012-11-15 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra prrs en vector viral
US9187731B2 (en) * 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
WO2013017568A1 (en) 2011-07-29 2013-02-07 Boehringer Ingelheim Vetmedica Gmbh INFECTIOUS cDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF
US9099230B2 (en) 2012-11-12 2015-08-04 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State Univesity Amorphous metal thin-film non-linear resistor
EP2968513A2 (en) 2013-03-15 2016-01-20 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
DK3083947T3 (da) 2013-12-20 2019-07-08 Boehringer Ingelheim Vetmedica Gmbh Prrs-virusvariant, cdna-klon af europæisk prrs-virus, samt anvendelser deraf

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592873B1 (en) * 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6773908B1 (en) * 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US20020012670A1 (en) * 2000-01-26 2002-01-31 Knut Elbers Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV)
US6841364B2 (en) * 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof

Also Published As

Publication number Publication date
KR20070028431A (ko) 2007-03-12
AR049825A1 (es) 2006-09-06
WO2006002193A2 (en) 2006-01-05
MXPA06014821A (es) 2007-03-26
WO2006002193A3 (en) 2006-03-02
US7722878B2 (en) 2010-05-25
TW200603825A (en) 2006-02-01
US20080038293A1 (en) 2008-02-14
JP2008503221A (ja) 2008-02-07
RU2007101531A (ru) 2008-07-27
EP1755664A2 (en) 2007-02-28
DK1755664T3 (en) 2015-08-24
EP1755664B1 (en) 2015-06-10
CA2570778A1 (en) 2006-01-05
BRPI0510930A (pt) 2007-11-20
AU2005258092A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
ES2546933T3 (es) Vacunas de subunidades contra el PRRSV
Lavelle et al. Mucosal vaccines—fortifying the frontiers
Plotkin History of vaccination
JP5779352B2 (ja) 複製欠損フラビウイルスワクチンおよびワクチンベクター
ES3017307T3 (en) Nucleic acid molecules and uses thereof
ES2251162T3 (es) Clon infeccioso con cdna de virus del sindrome reproductor y respiratorio porcino norteamericano (prrs) y sus usos.
JP5619004B2 (ja) 高病原性ブタ繁殖・呼吸障害症候群（ｈｐｐｒｒｓ）のワクチン
TWI760322B (zh) 重組腺病毒載體裝載之fmdv疫苗及其用途
He et al. Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg
PT835930E (pt) Estirpes europeias de vacina do virus do sindroma reprodutivo e respiratorio porcino (prrsv)
Gao et al. Porcine reproductive and respiratory syndrome virus expressing E2 of classical swine fever virus protects pigs from a lethal challenge of highly-pathogenic PRRSV and CSFV
Xu et al. Immunogenicity in swine of orally administered recombinant Lactobacillus plantarum expressing classical swine fever virus E2 protein in conjunction with thymosin α-1 as an adjuvant
BRPI0709282B1 (pt) vacina contra estreptococos
Reyes et al. A novel “in-feed” delivery platform applied for oral DNA vaccination against IPNV enables high protection in Atlantic salmon (Salmon salar)
WO2010107847A1 (en) Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
CA3029108A1 (en) Duck enteritis virus and the uses thereof
Jiang et al. Humoral immune response induced by oral administration of S. typhimurium containing a DNA vaccine against porcine reproductive and respiratory syndrome virus
Comber et al. Gold nanoparticles (AuNPs): A new frontier in vaccine delivery
Mingxiao et al. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18
Koolaparambil Mukesh et al. Beyond COVID-19: the promise of next-generation coronavirus vaccines
ES2655190T3 (es) Prevención y tratamiento de la infección por Mycobacterium
KR20140105781A (ko) 신규한 약독화된 폴리오바이러스: pv-1 모노-cre-x
Yu et al. Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3
ES2967066T3 (es) Composiciones para su uso como agente profiláctico para aquellos en riesgo de infección de tuberculosis, o como agentes secundarios para tratar pacientes infectados con tuberculosis
Xu et al. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera